​

Verve Therapeutics Ownership | Who Owns Verve Therapeutics?

OverviewForecastRevenueFinancialsChart

Verve Therapeutics Ownership Summary

Verve Therapeutics is owned by 89.26% institutional investors, 1.78% insiders, and 8.96% retail investors. Alphabet is the largest institutional shareholder, holding 14.85% of VERV shares. ARK Genomic Revolution is the top mutual fund, with 2.92% of its assets in Verve Therapeutics shares.

VERV Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockVerve Therapeutics89.26%1.78%8.96%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Alphabet12.35M14.85%$60.26M
Blackrock6.62M7.96%$32.31M
Vanguard group5.26M6.33%$25.69M
T. rowe price investment management4.53M5.45%$22.10M
State street3.35M4.03%$16.35M
Casdin capital3.06M3.68%$14.93M
Novo2.40M2.89%$11.71M
Arch venture management2.01M2.42%$9.80M
Baker bros. advisors lp1.69M2.03%$8.25M
Jpmorgan chase1.69M2.03%$8.25M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Arch venture management2.01M3.69%$9.80M
Alphabet12.35M3.05%$60.26M
Casdin capital3.06M1.14%$14.93M
Novo2.40M0.59%$11.71M
Redmile group1.46M0.43%$7.14M
Palo alto investors lp575.82K0.33%$2.81M
Ecor1 capital1.25M0.19%$6.10M
Vestal point capital, lp500.00K0.18%$2.44M
Pdt partners333.86K0.15%$1.63M
Baker bros. advisors lp1.69M0.11%$8.25M

Top Buyers

HolderShares% AssetsChange
Blackrock6.62M0.00%1.25M
Jacobs levy equity management905.82K0.02%905.82K
Vestal point capital, lp500.00K0.18%500.00K
Goldman sachs group1.29M0.00%457.38K
Novo2.40M0.59%400.00K

Top Sellers

HolderShares% AssetsChange
Ark investment management---2.94M
Federated hermes1.15M0.01%-2.41M
Fmr1.42M0.00%-1.96M
State street3.35M0.00%-1.75M
Nikko asset management americas---1.12M

New Positions

HolderShares% AssetsChangeValue
Jacobs levy equity management905.82K0.02%905.82K$4.42M
Vestal point capital, lp500.00K0.18%500.00K$2.44M
Los angeles capital management242.47K0.00%242.47K$1.18M
Gsa capital partners llp203.68K0.07%203.68K$994.00K
Mirae asset global etfs144.03K0.00%144.03K$702.18K

Sold Out

HolderChange
Financial gravity asset management-3.00
Nelson, van denburg & campbell wealth management group-11.00
Riggs asset managment-22.00
Hollencrest capital management-53.00
Entrypoint capital-92.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241766.67%75,178,380-1.22%891.06%971.04%44-4.35%
Jun 30, 2024165-76,110,149-6.75%910.95%96-4.95%4615.00%
Mar 31, 20241652.48%81,620,7739.25%980.85%101-8.18%4060.00%
Dec 31, 202316113.38%74,711,87916.98%1071.05%11025.00%258.70%
Sep 30, 202314213.60%63,865,0803.21%1011.01%8839.68%23-39.47%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Genomic Revolution2.47M2.92%-340.12K
SPDR® S&P Biotech ETF2.33M2.75%25.74K
Vanguard Total Stock Mkt Idx Inv2.15M2.54%-
iShares Russell 2000 ETF1.83M2.16%-4.12K
T. Rowe Price Small-Cap Value1.24M1.47%-38.25K
Vanguard Institutional Extnd Mkt Idx Tr982.73K1.16%-3.83K
T. Rowe Price US Small-Cap Core Equity910.26K1.08%-41.87K
CREF Stock R1868.91K1.03%175.51K
Vanguard Small Cap Index850.11K1.00%2.01K
Fidelity Small Cap Index730.55K0.86%-16.16K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 02, 2024Dorval Allison Chief Financial OfficerSell$3.13K
May 14, 2024Ashe Andrew D. See RemarksBuy$475.76K
Apr 02, 2024Nickerson Joan Chief Administrative OfficerSell$12.48K
Dec 01, 2023Yeshwant Krishna Buy$18.00M
Nov 29, 2023Dorval Allison Chief Financial OfficerSell$6.34K

Insider Transactions Trends

DateBuySell
2024 Q4-1
2024 Q211
2024 Q1--
2023 Q411
2023 Q3--

VERV Ownership FAQ

Who Owns Verve Therapeutics?

Verve Therapeutics shareholders are primarily institutional investors at 89.26%, followed by 1.78% insiders and 8.96% retail investors. The average institutional ownership in Verve Therapeutics's industry, Biotech Stocks , is 47.04%, which Verve Therapeutics exceeds.

Who owns the most shares of Verve Therapeutics?

Verve Therapeutics’s largest shareholders are Alphabet (12.35M shares, 14.85%), Blackrock (6.62M shares, 7.96%), and Vanguard group (5.26M shares, 6.33%). Together, they hold 29.15% of Verve Therapeutics’s total shares outstanding.

Does Blackrock own Verve Therapeutics?

Yes, BlackRock owns 7.96% of Verve Therapeutics, totaling 6.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.31M$. In the last quarter, BlackRock increased its holdings by 1.25M shares, a 23.20% change.

Who is Verve Therapeutics’s biggest shareholder by percentage of total assets invested?

Arch venture management is Verve Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.69% of its assets in 2.01M Verve Therapeutics shares, valued at 9.8M$.

Who is the top mutual fund holder of Verve Therapeutics shares?

ARK Genomic Revolution is the top mutual fund holder of Verve Therapeutics shares, with 2.92% of its total shares outstanding invested in 2.47M Verve Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools